{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:04:54Z","timestamp":1790625894959,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The primary objective of this study is to systematically monitor and comprehensively characterize adverse events (AEs) associated with methimazole, which is utilized in the treatment of hyperthyroidism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A comprehensive analysis of the US FDA Adverse Event Reporting System (FAERS) database was conducted, covering data from the first quarter of 2004 to the first quarter of 2025. Multiple signal detection algorithms, including the ROR, PRR, BCPNN, and EBGM, were employed for conduct disproportionality analysis to efficiently mine the data and accurately identify signals associated with AEs related to methimazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>After analyzing 1,908 patient cases with 6,449 reported AEs linked to methimazole, the study confirmed AEs like agranulocytosis, pyrexia, hypothyroidism, and drug-induced liver injury aligning with the drug\u2019s package insert. Interestingly, several previously unreported AEs, such as premature baby, polyarthritis, pleural effusion, septic shock, cholestasis and jaundice cholestatic were identified. The findings indicate potential unrecognized AEs and highlight the importance of continued pharmacovigilance and rigorous drug safety surveillance. The median onset time of methimazole related AEs was 27 days (interquartile range [IQR]: 5\u201358 days), indicating that the majority of cases occurred early after initiating use methimazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study confirms that agranulocytosis, pyrexia, exposure during pregnancy, and hyperthyroidism are AEs associated with methimazole use. It also identifies new safety signals, including premature infants, polyarthritis, pleural effusion, septic shock, cholestasis, and cholestatic jaundice, that warrant further investigation. These findings support deeper analysis of the relationship between methimazole and adverse events and may help improve patient safety and clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1680281","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:18:08Z","timestamp":1759292288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025"],"prefix":"10.3389","volume":"16","author":[{"given":"Yixin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1613223","article-title":"A higher composite dietary antioxidant index is associated with a decreased risk of subclinical hyperthyroidism in adults: evidence from epidemiological studies","volume":"12","author":"Wu","year":"2025","journal-title":"Front Nutr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00005-0","article-title":"Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis","volume":"11","author":"Wiersinga","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.44.511.363","article-title":"aetiology and pathogenesis of hyperthyroidism","volume":"44","author":"Hetzel","year":"1968","journal-title":"Postgrad Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02354.x","article-title":"Hyperthyroidism: a risk factor for female sexual dysfunction","volume":"8","author":"Atis","year":"2011","journal-title":"J Sex Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-023-03679-y","article-title":"Perchlorates in the treatment of hyperthyroidism and thyrotoxicosis: a comprehensive review","volume":"85","author":"Lisco","year":"2024","journal-title":"Endocrine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.727","article-title":"Fetal and neonatal hyperthyroidism","volume":"9","author":"Zimmerman","year":"1999","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000438","article-title":"Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation","volume":"38","author":"Chiera","year":"2023","journal-title":"Int Clin Psychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2013.831044","article-title":"Severe fetal and neonatal hyperthyroidism years after surgical treatment of maternal Graves\u2019 disease","volume":"34","author":"Dierickx","year":"2014","journal-title":"J Obstet Gynaecol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01148-w","article-title":"Treatment of Graves\u2019 hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy","volume":"43","author":"Tonacchera","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1210\/er.2006-0043","article-title":"The clinical significance of subclinical thyroid dysfunction","volume":"29","author":"Biondi","year":"2008","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmr024","article-title":"Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review","volume":"17","author":"Boogaard","year":"2011","journal-title":"Hum Reprod Update"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jor.1100170617","article-title":"Inhibition of endochondral ossification during fracture repair in experimental hypothyroid rats","volume":"17","author":"Urabe","year":"1999","journal-title":"J Orthop Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with graves\u2019 Disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123934","DOI":"10.1016\/j.saa.2024.123934","article-title":"Fe single atoms encapsulated in N, P-codoped carbon nanosheets with enhanced peroxidase-like activity for colorimetric detection of methimazole","volume":"310","author":"Zhang","year":"2024","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0031","article-title":"Long-term methimazole therapy in Graves\u2019 hyperthyroidism and adverse reactions: a Danish multicenter study","volume":"11","author":"Karmisholt","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2018.05.014","article-title":"Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study","volume":"85","author":"Andrade","year":"2019","journal-title":"Braz J Otorhinolaryngol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1644241","article-title":"Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system","volume":"16","author":"Yu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103385","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5265","article-title":"More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis","volume":"30","author":"Hauben","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000342920","article-title":"Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy","volume":"1","author":"Taylor","year":"2012","journal-title":"Eur Thyroid J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.947323","article-title":"Methimazole-induced pancytopenia with ANCA positivity: diagnostic and management challenges","volume":"26","author":"Valasareddy","year":"2025","journal-title":"Am J Case Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286097","article-title":"Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis","volume":"18","author":"Liu","year":"2023","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1210\/jc.2007-0141","article-title":"Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline","volume":"92","author":"Abalovich","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-23-0031","article-title":"Antithyroid arthritis syndrome caused by methimazole in a patient with Graves\u2019 disease","volume":"2023","author":"Kawasumi","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5748938","DOI":"10.1155\/2019\/5748938","article-title":"Methimazole-induced pleural effusion in the setting of graves\u2019 Disease","volume":"2019","author":"Khine","year":"2019","journal-title":"Case Rep Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1680281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:18:09Z","timestamp":1759292289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1680281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":31,"alternative-id":["10.3389\/fendo.2025.1680281"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1680281","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1680281"}}